Covid-19 Is derailing cancer clinical trials. Is new technology required to get them back on track?

Paper made silhouettes with one of them of orange color to stand out from the rest

The coronavirus pandemic has affected every aspect of American healthcare. Some have postponed medical, dental or vision appointments for themselves or family members out of fear of contracting the virus. Many providers have deferred nonessential visits to slow the pandemic’s spread and keep critical staff available to treat patients with Covid-19.

The clinical trial cycle is also experiencing significant disruption. One leading oncology practice publication notes that new cancer diagnoses are down 37% since the pandemic began, and IQVIA data shows that “22 million people postponed cancer screening tests and 80,000 patients delayed or missed diagnoses.” (IQVIA is an investor in Inteliquet, the company I lead as president and COO).

How do we ensure that the right patient can still access the right drug at the right time, at a time when many oncology clinical trials which would provide a much-needed treatment option have been delayed?

A Cancer Diagnosis Has

Read More

Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc. are entering into a collaboration to sequence the complete human genomes of thousands of consenting patients, in order to identify genetic alterations driving disease and potentially reveal previously unidentified therapies for treatment. The initiative, which also includes a collaboration between Weill Cornell Medicine, NewYork-Presbyterian Hospital, and the New York Genome Center (NYGC), aims to evaluate the diagnostic potential of whole-genome sequencing at scale, which allows the interrogation of the full genome sequence of a patient’s DNA. The goal is to better understand health problems and potential disease risks of individual patients, and to design more effective treatments, including the choice of specific drugs and their dosing.

Investigators will study the feasibility and viability of large-scale implementation of whole-genome sequencing within an academic medical center that is part

Read More

At 12.6% CAGR, Clinical Trial Management System Market Size | Global Industry Analysis and Opportunity Assessment 2020-2025

The MarketWatch News Department was not involved in the creation of this content.

Nov 29, 2020 (Heraldkeepers) —
Clinical Trial Management System Market is valued at USD 662.4 Million in 2019 and expected to reach USD 1520.3 Million by 2026 with the CAGR of 12.6% over the forecast period.

Global Clinical Trial Management System Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2026- Increasing R&D investment by the pharmaceutical, life science, and clinical research industries is one of the major factors driving the growth of Global Clinical Trial Management System Market

Get Sample of This [email protected]

Scope of Global Clinical Trial Management System Market-

It is a software system used by biotechnological and pharmaceutical industries to manage clinical trials in clinical research. It involves management of clinical trial records in clinical research. It starts from planning of research proposal to preparation, conduct of trial, report generation, CTMS maintenance

Read More

Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ — Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics,  announced today that it will host a live webcast event to provide a clinical update from the company’s ongoing dose escalation Phase 1 study of STRO-002, a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC), for patients with ovarian cancer. The results presented will follow-up on previously presented data, based on a new data cut-off date of Oct. 30, 2020. The company will also give an update on the program expansion cohorts in ovarian and endometrial cancer. The virtual KOL Discussion of STRO-002 Data will be held on Thursday, Dec. 3, 2020, at 5pm ET / 2pm PT.

The data will be presented and discussed by

Read More

Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer

STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the publication of a second abstract at the San Antonio Breast Cancer Symposium (SABCS), jointly authored by Professor Mothaffar F. Rimawi, the Global Principal Investigator of the GP2 Phase III clinical trial, and the Executive Medical Director and Co-Leader of the Breast Cancer Program at the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, and Professor C. Kent Osborne, Tina and Dudley Sharp Chair in Oncology and the founding Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. The abstract will be displayed as the Company’s second poster on Wednesday, December 9, 2020 in a virtual format with an introductory audio track.

The abstract highlights

Read More

Neonatal Warmer Market Clinical Reviews by Expert, Emerging Technology And Healthcare Analysis 2020-2025

The MarketWatch News Department was not involved in the creation of this content.

Nov 23, 2020 (Market Insight Reports) —
The Market Intelligence Data has published the obtain ability of a new statistical data to its repository titled as, Neonatal Warmer Market. The report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Inquire for Sample Copy of this Report:

Prominent Key Players – GE Healthcare (NYSE: GE), Dison, Drager, Advanced, Atom Medical, Natus Medical, DAVID, Phoenix Medical, Fanem, JW Medical, Mediprema, Medicor, Weyer, Cobams

Key players of the global Neonatal Warmer are profiled on the basis of various factors, which include recent developments, business strategies, financial

Read More

Clinical trial reverses two biological processes associated with aging in human cells — ScienceDaily

A new study from Tel Aviv University (TAU) and the Shamir Medical Center in Israel indicates that hyperbaric oxygen treatments (HBOT) in healthy aging adults can stop the aging of blood cells and reverse the aging process. In the biological sense, the adults’ blood cells actually grow younger as the treatments progress.

The researchers found that a unique protocol of treatments with high-pressure oxygen in a pressure chamber can reverse two major processes associated with aging and its illnesses: the shortening of telomeres (protective regions located at both ends of every chromosome) and the accumulation of old and malfunctioning cells in the body. Focusing on immune cells containing DNA obtained from the participants’ blood, the study discovered a lengthening of up to 38% of the telomeres, as well as a decrease of up to 37% in the presence of senescent cells.

The study was led by Professor Shai Efrati of

Read More Secures $11M Series A Funding to Assist Healthcare Organizations Improve Clinical and Financial Outcomes

AUSTIN, Texas–(BUSINESS WIRE)–, Healthcare’s Data Science Platform, today announced the close of an $11 million Series A. The investment round was co-led by Greycroft and .406 Ventures with participation from Silicon Valley Bank and Meridian Street Capital. ClosedLoop makes it easy and affordable for healthcare organizations to use data science to improve outcomes and reduce costs by combining an intuitive end-to-end machine learning platform for data scientists with a catalog of healthcare specific predictive models and features.

The company’s technology is already recognized as a category leader by clients and the KLAS Healthcare AI 2020 report, which highlighted ClosedLoop as a Top Performer in healthcare-focused AI with 100% of customers saying they would buy the platform again. ClosedLoop is also a top 7 finalist in the Centers for Medicare & Medicaid Services (CMS) Artificial Intelligence (AI) Health Outcomes Challenge.

ClosedLoop’s platform provides leading-edge AI tools and automation capabilities

Read More

Catalog Management System Market : Advancements and Efficient Clinical Outcomes would Drive the Industry Growth with Top Key Player’s Analysis

The MarketWatch News Department was not involved in the creation of this content.

Nov 17, 2020 (AmericaNewsHour) —
Global Catalog Management System Market to reach USD 1460.2 million by 2025.Global Catalog Management System Market valued approximately USD 761 million in 2016 is anticipated to grow with a healthy growth rate of more than 7.51% over the forecast period 2018-2025. Improvement in information technology systems that fulfill customers’ requirements and increasing use of the internet for business are driving the growth in the Global Catalog Management System Market. However, the risk associated with data security and lack of awareness about the utilities and benefits of catalog management systems hinder the growth in the market. A catalog management system is used to edit online catalogs, thus enables suppliers to price the goods available. It is a process that helps suppliers to quickly modify the changes in product and price, and introduce new … Read More

CMIC Supports Clinical Trials for Digital Therapeutics Using SUSMED’s Trial Management System

CMIC Co., Ltd. (henceforth “CMIC”)(TOKYO:2309) has launched services using SUSMED, Inc.’s (henceforth “SUSMED”) trial management system covering subject registration, software assignment and distribution for digital therapeutics (DTx).
The system is able to overcome the common challenges of DTx clinical trials, ensuring blinded assignment and preventing unauthorized access. By employing this system, CMIC will offer more efficient operations for DTx trials, such as for the assignment and delivery of software applications (apps) to trial participants, cutting development costs.

This press release features multimedia. View the full release here:

*The system allows for seamless management of both intervention/sham app assignment and app distribution. (Graphic: Business Wire)

In a DTx clinical trial, the software app must be installed on a device, such as a smartphone. Additionally, a placebo app (sham) is often used as a control in comparison to the actual treatment app (intervention), so it is essential that each app is

Read More